Navigation Links
GeneGo Integrates With Cytoscape
Date:12/18/2007

ST. JOSEPH, Mich., Dec. 18 /PRNewswire/ -- GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that its platforms for functional data analysis, MetaCore and MetaDrug, are now integrated with Cytoscape. MetaCore users will now be able to use Cytoscape network visualization tools and have access to dozens of its open source and commercial plug-ins. The integrated solution was presented at the Cytsocape annual meeting in Amsterdam, November 6-9.

Originally developed at the Institute for Systems Biology, Cytoscape is a bioinformatics software platform for visualizing molecular interaction networks and integrating these interactions with gene expression profiles and other state data. Additional features are available as plugins. Plugins are available for network and molecular profiling analyses, new layouts, additional file format support and connection with databases. Plugins may be developed using the Cytoscape open Java software architecture by anyone and plugin community development is encouraged.

"This was an obvious progression from our relationship with the Institute of Systems Biology," said Julie Bryant, Vice President of Business Development for GeneGo. "The Cytoscape project has grown into, probably, the most advanced and well known developer's community in systems biology, and we are very glad to participate in it. We know that our tools and content will be of interest for Cytoscape users."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM) and MetaMiner(TM), 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.

About the Institute for Systems Biology

The Institute for Systems Biology (ISB) is an internationally renowned, non-profit research institute dedicated to the study and application of systems biology. ISB seeks to unravel the mysteries of human biology and identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. The driving force behind the innovative "systems" approach is the integration of biology, computation and technology. This approach allows scientists to analyze all of the elements in a system rather than one gene or protein at a time. Located in Seattle, Washington, the Institute has grown to 13 faculty and more than 200 staff members; an annual budget of more than $26 million; and an extensive network of academic and industrial partners. For more information about the ISB visit: http://www.systemsbiology.org


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
2. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
3. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , February 17, 2017 ... "Biomarkers Market by Product (Consumables, Service), Type (Safety, ... (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - ... market is projected to reach USD 53.34 Billion ... growing at a CAGR of 13.8% during the ...
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, ... data on its oral peptide drug candidates, PTG-100 ... of the European Crohn,s and Colitis Organization (ECCO).  ... Barcelona, Spain from February 15 ... detail preclinical data on Protagonist drug candidates PTG-100 ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, ... focused on venture growth investments in biotechnology and ... Josh Richardson , M.D. to Managing Director. ... companies.  He is a board observer at InfaCare ... Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence ...
(Date:2/16/2017)...   Capricor Therapeutics, Inc. (NASDAQ: ... first-in-class biological therapies for cardiac and other medical ... terminate its license agreement with the Mayo Clinic ... "Our decision to return these rights ... efforts to advance our core cell and exosome-based ...
Breaking Biology Technology:
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
(Date:1/19/2017)... Jan. 19, 2017 Sensory Inc ... and security for consumer electronics, and i ... systems and cybersecurity solutions, today announced a global ... financial institutions worldwide to bolster security of data ... secure user authentication platforms they offer, innerCore now ...
(Date:1/12/2017)... DIEGO , Jan. 12, 2017  Trovagene, Inc. ... tumor DNA (ctDNA) technologies, today announced that it has ... Europe and the Middle East ... tests.  This milestone marks the first wave of international ... for urine and blood samples. The initial ...
Breaking Biology News(10 mins):